Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 0.88 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.88 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.51 |
| ▸ | AKT2 | P31751 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091456 | 0.94 | PIM1 (1.00) | PIM1PIM2PDPK1AKT2PDGFRB | |
| SCHEMBL699128 | 0.91 | PIM1 (1.00) | PIM1PIM2PDPK1AKT2CHEK1 | |
| SCHEMBL699129 | 0.91 | PIM1 (1.00) | PIM1PIM2PDPK1AKT2CHEK1 | |
| SCHEMBL10091778 | 0.90 | PIM1 (0.79) | PIM1PIM2PDPK1AKT2CHEK1 | |
| SCHEMBL10091560 | 0.87 | PIM1 (0.68) | PIM1PIM2CHEK1PDGFRBFGFR1 | |
| SCHEMBL10091543 | 0.86 | PIM1 (1.00) | PIM1PIM2PDPK1AKT2PDGFRB | |
| SCHEMBL10091434 | 0.86 | PIM1 (0.83) | PIM1PIM2PDPK1AKT2PDGFRB | |
| SCHEMBL10091474 | 0.86 | PIM1 (0.82) | PIM1PIM2PDPK1AKT2CHEK1 | |
| SCHEMBL10091570 | 0.85 | PIM1 (0.81) | PIM1PIM2PDPK1AKT2CHEK1 | |
| SCHEMBL10091440 | 0.85 | PIM1 (0.84) | PIM1PIM2PDPK1AKT2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PIM2 3/4885PDPK1 113/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PIM2 3/4885PDPK1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.